NASDAQ: INMB · Life Sciences · 4 alerts · CIK 1711754
Share price
$0.9464Close, Nov 16
Market cap
$29.3M
Shares outstanding
30.96MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inmune Bio, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, INmune Bio reported a net loss of $11.4 million, a significant reduction from the $40.7 million loss in the prior year period which included a $16.5 million impairment charge. The company reported zero revenue for the 2026 period and expressed substantial doubt about its ability to continue as a going concern due to insufficient liquidity to sustain operations for the next twelve months.
INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor for a $4.5 million registered direct offering and concurrent private placement. The company is issuing 3,000,000 shares of common stock at $1.50 per share along with warrants to purchase an additional 3,000,000 shares at an exercise price of $1.65. Proceeds are intended for working capital and general corporate purposes.
INmune Bio filed a formal investor presentation deck and announced a Master Services Agreement with Uniphar to establish a commercialization framework for Ebstrocel. The partnership will initially focus on named-patient access in Europe and the MENA region, providing a capital-efficient infrastructure for international distribution. Additionally, the company submitted a pre-Marketing Authorisation Application to the UK MHRA for Ebstrocel.
INmune Bio, Inc. has expanded its Board of Directors to seven members and appointed R. Duane Clark II and James Sapirstein as independent directors. Mr. Clark currently leads Sanofi's U.S. Rare Diseases business, while Mr. Sapirstein is the CEO of Cocrystal Pharma and has extensive experience in biopharma business development and licensing. These appointments are intended to strengthen the company's commercialization planning for Ebstrocel and its strategic partnering capabilities.